A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery

Model scores of the 29,894 trials active now.

Model score 17% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 13% of the time (1,304 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-11-05. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: or equalequal torandomizationin subjectsdefined
  Phrases that lowered it: participantkneekgjnjcontraceptive
• Sponsor's past termination rate: 8.7% (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Primary purpose: prevention (lowers risk) · Design
• Drug's FAERS reports with a death: 12.6% (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Number of arms: 11 (lowers risk) · Design
• Blinding: double (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 118 (lowers risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 16770 (lowers risk) · Drug's FDA history
• Minimum age: 50 (raises risk) · Who can join
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports marked serious: 72.8% (lowers risk) · Drug's FDA history
• Sponsor's past trials: 310 (raises risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery NCT03891524 · started 2019 · scored riskier than 58% of active trials completed
• Study of Local Administration of DepoTXA for Reduced Postsurgical Bleeding in Subjects Undergoing TKA NCT02922582 · started 2016 · scored riskier than 27% of active trials terminated
• Dose-confirmatory Bridging Study in Total Knee Replacement NCT01206972 · started 2010 · scored riskier than 10% of active trials completed
• A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement Surgery NCT00595426 · started 2008 · scored riskier than 10% of active trials completed
• Clinical Study on the Efficacy and Safety of Multiple Oral Administrations of SHR2285 Tablets in Patients Undergoing Elective Total Knee Arthroplasty NCT05203705 · started 2022 · scored riskier than 13% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.